These data suggested that JQ1, the most efficient drug inhibiting MYCN oncogene functions, does not show immunomodulatory capacity in terms of induction of ligands for NK cell-activating receptors and NK cell anti-tumor activity in NB cell lines. The gene discussed is MYCN; the disease is neoplasm.